ISB News

Scientific Wellness Meets Personalized Nutrition

Dr. Lee Hood, ISB president, and Nathan Price, ISB associate director, have joined the scientific advisory board of the newly launched Habit, which will begin to offer personalized nutrition plans based on your biology. From a recent Fast Company article:

Neil Grimmer’s new startup, called Habit, aims to help others achieve their goals, whether it’s to lose weight or sleep more soundly. The company, which is launching in January, offers a $299 blood test to screen for 60 biomarkers, including amino acids, vitamin levels, and blood sugar, as well as some genetic variants that may play a role in how an individual responds to diet. The company is also attempting to test a users’ metabolic rate through a “challenge,” which involves drinking a milkshake-like beverage to understand how they respond to fats, carbs and sugars, and then sending in another set of blood tests. Read more…

 

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.